| (210) | Number of the EPO application | 19803950 |
| (220) | Filing date of the EPO application | 2019.05.15 |
| (80) | EPO patent specification publication (B) | EPB nr. 18/2026, 2026.04.29 |
| (110) | EPO patent number | 3793606 |
| (21) | Number of the application | e 2021 0271 |
| (71) | Name(s) of applicant(s), code of the country | Janssen Biotech, Inc., US;
Stichting Amsterdam UMC, NL; |
| (72) | Name(s) of inventor(s), code of the country | ADAMS Homer, US;
GAUDET Francois, US;
FRERICHS Kris, NL;
VAN DE DONK Niels, NL;
VERKLEIJ Christie C.P.M., NL; |
| (73) | Name(s) of owner(s), code of the country | JANSSEN BIOTECH INC., US;
Stichting Amsterdam UMC, NL; |
| (54) | Title of the invention | METHODS OF TREATING CANCERS AND ENHANCING EFFICACY OF T CELL REDIRECTING THERAPEUTICS |
| (13) | Kind-of-document code | A1 |
| (51) | International Patent Classification | A61K 39/395 (2006.01.01); A61K 45/06 (2006.01.01); C07K 16/28 (2006.01.01); C07K 16/30 (2006.01.01); A61K 31/454 (2006.01.01); A61K 31/69 (2006.01.01); A61K 39/00 (2006.01.01) |
| (52) | Cooperative Patent Classification | C07K 16/2809 (EP); A61K 31/454 (EP); A61K 31/69 (EP); A61K 39/39558 (EP); A61K 45/06 (EP); C07K 16/2878 (EP); C07K 16/3061 (EP); A61K 2039/505 (EP); C07K 2317/21 (EP); C07K 2317/31 (EP); C07K 2317/33 (EP); C07K 2317/34 (EP); C07K 2317/515 (EP); C07K 2317/565 (EP); C07K 2317/76 (EP); C07K 2317/92 (EP)
A61K 31/454, A61K 2300/00 (EP);
A61K 31/69, A61K 2300/00 (EP); |
| (19) | Country | US |
| (41) | Date of publication of the application | 2021.04.30 |
| (30) | Priority | 201862672222 P, 2018.05.16, US; 201862736804 P, 2018.09.26, US; 201962842080 P, 2019.05.02, US |
| (86) | International application | PCT/IB2019/054034, 2019.05.15 |
| (87) | International publication | WO 2019/220369, 2019.11.21 |